NASDAQ:EGLT - Egalet Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.01
+0.30 (1.20%)
Get New Egalet Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EGLT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EGLT

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Egalet in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a -100.00% upside from the last price of $0.01.

This chart shows the closing price for EGLT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Egalet. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/26/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/27/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/25/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/21/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/27/2018JMP SecuritiesDowngradeOutperform ➝ UnderperformLow
8/9/2018JMP SecuritiesLower Price TargetMarket Outperform ➝ Market Outperform$4.00 ➝ $1.50High
6/15/2018Cantor FitzgeraldReiterated RatingNeutralLow
5/22/2018Cantor FitzgeraldDowngradeOverweight ➝ NeutralLow
5/8/2018Cantor FitzgeraldDowngradeOverweight ➝ Hold$2.00Low
3/13/2018Cantor FitzgeraldLower Price TargetOverweight ➝ Overweight$7.00 ➝ $3.50High
3/12/2018Cantor FitzgeraldSet Price TargetBuy$4.00Low
1/3/2018Stifel NicolausDowngradeBuy ➝ Hold$1.50High
12/15/2017Cantor FitzgeraldSet Price TargetBuy$7.00High
11/28/2017Cantor FitzgeraldSet Price TargetBuy$7.00High
11/16/2017Cantor FitzgeraldSet Price TargetBuy$7.00N/A
11/9/2017GabelliDowngradeBuy ➝ HoldN/A
8/26/2017Cantor FitzgeraldReiterated RatingBuyLow
8/20/2017Cantor FitzgeraldReiterated RatingOverweightLow
8/14/2017Cantor FitzgeraldReiterated RatingOverweight$7.00High
8/14/2017GuggenheimSet Price TargetBuy$7.00High
8/10/2017Stifel NicolausReiterated RatingBuy ➝ Buy$14.00 ➝ $6.00High
7/14/2017JMP SecuritiesLower Price TargetMarket Outperform$15.00 ➝ $6.00Medium
6/8/2017Cantor FitzgeraldSet Price TargetBuy$8.00High
6/1/2017Cantor FitzgeraldReiterated RatingBuy$8.00Low
(Data available from 5/22/2017 forward)

News Sentiment Rating

0.39 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/24/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/23/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/22/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/21/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
3/23/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/22/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/22/2022

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Egalet logo
Egalet Corporation, a specialty pharmaceutical company, develops, manufactures, and commercializes treatments for patients with pain and other conditions. It has licensed three approved pain products, such as SPRIX Nasal Spray, a non-steroidal anti-inflammatory drug indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level; OXAYDO, an immediate-release oxycodone product designed to discourage abuse via snorting for the management of acute and chronic pain severe enough to require an opioid analgesic, and for which alternative treatments are inadequate; and ARYMO ER, an extended-release (ER) morphine product formulated with abuse-deterrent (AD) properties for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The company is also developing Egalet-002, a Guardian Technology AD, ER, oral oxycodone formulation, which is in Phase III clinical trials for the same indication as ARYMO ER. In addition, its other products include Egalet-003, an AD stimulant product candidate; and Egalet-004, an AD, ER hydrocodone-based product candidate. The company has a collaboration and license agreement with Acura Pharmaceuticals, Inc. to commercialize OXAYDO tablets; and Septodont, Inc. to promote SPRIX Nasal Spray. Egalet Corporation was founded in 2010 and is headquartered in Wayne, Pennsylvania.
Read More

Today's Range

Now: $0.01
Low: $0.01
High: $0.01

50 Day Range

MA: $0.24
Low: $0.01
High: $0.33

52 Week Range

Now: $0.01
Low: $0.03
High: $1.57

Volume

N/A

Average Volume

853,425 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Egalet?

The following Wall Street sell-side analysts have issued stock ratings on Egalet in the last year:
View the latest analyst ratings for EGLT.

What is the current price target for Egalet?

0 Wall Street analysts have set twelve-month price targets for Egalet in the last year.
View the latest price targets for EGLT.

What is the current consensus analyst rating for Egalet?

Egalet currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for EGLT.

How do I contact Egalet's investor relations team?

Egalet's physical mailing address is 600 LEE ROAD SUITE 100, WAYNE PA, 19087. The specialty pharmaceutical company's listed phone number is 610-833-4200 and its investor relations email address is [email protected] The official website for Egalet is www.egalet.com. Learn More about contacing Egalet investor relations.